DNA on XNYS, Health Care, Ginkgo Bioworks Holdings, Inc., job postings
Measures activity, not value. Not investment advice.
Quarterly revenue fell 29% to $27.7M and shares dropped 25% in a month.
BadFederal contracts and grants fell to $27.1M from $68.5M
BadRevenue for the last 12 months down 33% to $100.7M
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $27.7M, net loss $41.0M.
31 Dec 2021RevenueNet incomeNet losstallest bar $1.6B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$27.7M
-$41.0M
30 Jun 2026
$20.2M
-$46.7M
31 Mar 2026
$19.5M
-$82.6M
31 Dec 2025
$33.4M
-$80.8M
30 Sep 2025
$38.8M
-$80.8M
30 Jun 2025
$49.6M
-$60.3M
31 Mar 2025
$48.3M
-$91.0M
31 Dec 2024
$43.8M
-$107.5M
30 Sep 2024
$89.0M
-$56.4M
30 Jun 2024
$56.2M
-$217.2M
31 Mar 2024
$37.9M
-$165.9M
31 Dec 2023
$34.8M
-$211.7M
30 Sep 2023
$55.4M
-$302.9M
30 Jun 2023
$80.6M
-$173.3M
31 Mar 2023
$80.7M
-$205.0M
31 Dec 2022
$98.3M
-$176.5M
30 Sep 2022
$66.4M
-$669.1M
30 Jun 2022
$144.6M
-$668.8M
31 Mar 2022
$168.4M
-$590.5M
31 Dec 2021
$148.5M
-$1.6B
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$100.7M
$150.6M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
-33%
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$251.0M
-$339.5M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-243%
-216%
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-249%
-225%
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-52.7%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$84.5M
$495.5M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$84.5M (net cash)
-$495.5M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
4.8
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
4.0
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
1.2
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$1.4M
bought $0, sold $1.4M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-1.6%
180 13F filers vs 183
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
–
No 13F holdings or share count.
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
–
9.5M shares sold short (30 Oct 2026); no share count in the company's filings in our data
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
3.9
9.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+14%
8.3M shares sold short in the report before, 9.5M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
64%
64% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 57%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
17
Tracked since 20 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 20 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
-29%
$27.7M vs $38.8M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$27.1M
the 12 months before: $68.5M
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$270K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
19
19 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
9.5×
19 articles in the last 7 days; its usual week has 2.
Unusual now sharp changes in the last 90 days, compared with its own past
Lobbying spend $120K, 4.0× its usual level
Price $7.46 on 20 Nov 2026, -4.6% over 12 months (12-month range $5.48 to $14.98)
Sharp change
8-K and other filings
WARN layoff notice
Lobbying filing
Insider net buying (open market). Insiders sold a net $5.0M in the last 12 months (the 12 months before: -$406K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).Revenue per quarter. Revenue $27.7M in the latest quarter, -29% on a year earlier.Capital spending per quarter. Capital spending $2.0M in the latest quarter.Institutional holders (13F filers). 180 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.Federal obligations. Federal obligations: $29.6M published in the last 12 months, +476% on the 12 months before.Lobbying spend. Lobbying spend: $270K published in the last 12 months, +2600% on the 12 months before.Workers in WARN layoff notices. Workers in WARN layoff notices: 0 published in the last 12 months.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source.
17 open postings; careers site tracked since 20 Nov 2026. Most in Software engineering 41%, Research & science 18%, Chip design (ASIC / RTL / verification / physical design) 6%, Embedded & firmware 6%.
Reported lobbying spend: $120K in Q3 2026, $60K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
18 Nov 2025
New
Crossroads Strategies, LLCfor Ginkgo Bioworks, Inc.
Education and outreach on automated lab technology.MED
Issues related to synthetic biology; Issues relate to critical minerals; Issues related to covid.; Issues related to synthetic biology; Issues related to critical minerals.; Issues related to bio-security; Issues related to critical minerals.; Issues related to synthetic biology.Health issues, Science/technology, Defense, Agriculture
Cornerstone Government Affairs, Inc.for Perimeter Systems Inc, (Fka Ginkgo Bioworks, Inc.)
Educate key government stakeholders on Ginkgo Bioworks medical detection and synthetic biology activities in support of the Department.Budget, Defense, MED
Changes and notable records, by the date each became public
16 Oct 2026Lobbying change
reported $120K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× its normal quarter.
See the evidence
This period
$120K (the quarter ended 30 Sep 2026)
Normal quarter (median of 7 earlier)
$30K
Typical spread (median absolute deviation)
$10K
How far from its usual level
+4.5
History used
2,557 days
the quarter ended 30 Sep 20267 earlier quartersnormal: $30K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
booked $21.0M in federal contract and grant obligations in March 2026, against none in the same month last year.
See the evidence
This period
$21.0M (March 2026)
Normal month (median of 4 earlier)
$5K
Typical spread (median absolute deviation)
$5K
How far from its usual level
+21.0
Same month last year
$0
History used
1,566 days
March 20264 earlier monthsnormal: $5K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
booked $54.2M in federal contract and grant obligations in January 2025, 2.8× the same month last year.
Same month last year: $19.6M; its normal month is $672K.
See the evidence
This period
$54.2M (January 2025)
Normal month (median of 3 earlier)
$672K
Typical spread (median absolute deviation)
$672K
How far from its usual level
+53.5
Same month last year
$19.6M
History used
1,142 days
January 20253 earlier monthsnormal: $672K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
booked $10.2M in federal contract and grant obligations in September 2024, 5.8× the same month last year.
Same month last year: $1.8M; its normal month is $887K.
See the evidence
This period
$10.2M (September 2024)
Normal month (median of 2 earlier)
$887K
Typical spread (median absolute deviation)
$887K
How far from its usual level
+7.1
Same month last year
$1.8M
History used
1,019 days
September 20242 earlier monthsnormal: $887K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
booked $54.5M in federal contract and grant obligations in August 2024, 3.4× the same month last year.
Same month last year: $16.0M; its normal month is $16.0M.
See the evidence
This period
$54.5M (August 2024)
Normal month (median of 2 earlier)
$16.0M
Typical spread (median absolute deviation)
$5K
How far from its usual level
+24.1
Same month last year
$16.0M
History used
989 days
August 20242 earlier monthsnormal: $16.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
booked $19.0M in federal contract and grant obligations in January 2024, against none in the same month last year.
See the evidence
This period
$19.0M (January 2024)
Normal month (median of 2 earlier)
$336K
Typical spread (median absolute deviation)
$336K
How far from its usual level
+18.6
Same month last year
$0
History used
776 days
January 20242 earlier monthsnormal: $336K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
reported $180K of lobbying spend for the quarter ended 31 Mar 2023, 2.0× the same quarter last year.
Same quarter last year: $90K; its normal quarter is $90K.
See the evidence
This period
$180K (the quarter ended 31 Mar 2023)
Normal quarter (median of 8 earlier)
$90K
Typical spread (median absolute deviation)
$0
How far from its usual level
+4.5
Same quarter last year
$90K
History used
1,278 days
the quarter ended 31 Mar 20238 earlier quartersnormal: $90K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Showing the newest 40 of 78 entries; narrow the window or the kind of data to see older ones.
Not listed: 435 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001830214
Ticker
DNA
Domain
ginkgobioworks.com
Employer name
Ginkgo Bioworks, Inc. (1 unverified)
Hq location
MA|BOSTON|02210 (1 unverified)
Lobbying client
ginkgo bioworks, perimeter systems inc fka ginkgo bioworks
Name
Ginkgo Biosecurity, LLC, Ginkgo Bioworks Holdings, Inc., Ginkgo Bioworks, Inc, Ginkgo Bioworks Securities Corporation and 4 more
Uei
ED48JCA71333, V62PM6L4HV34
Wikidata
Q29026065
Wikipedia
Ginkgo Bioworks
DOL H-1B labor condition applications and PERM certifications5 data points27 Jul 2026 to 27 Jul 2026
Federal lobbying disclosures (LDA)10 records, 81 data points1 Jul 2019 to 30 Sep 2026
SEC Form 13F institutional holdings4 records, 189 data points30 Sep 2021 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)100 records23 Dec 2020 to 9 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)396 data points31 Dec 2018 to 30 Sep 2026
SEC Form 4 insider transactions370 records, 560 data points4 Oct 2022 to 21 Oct 2026
FINRA short interest (twice monthly)366 data points30 Sep 2021 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2602 data points17 Sep 2021 to 20 Nov 2026
USASpending.gov federal awards6 records, 196 data points16 Dec 2021 to 28 Sep 2026
WARN layoff notices (state labor agencies)1 record, 3 data points17 Jun 2024 to 17 Jun 2024
Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026